Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Saccharomyces boulardii CNCM I-745 and Amoxicillin on the gut microbiota of healthy volunteers
2016-003654-33Phase 2Completed
- Sponsor
- Biocodex
- Start
- Oct 2016
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of saccharomyces boulardii and amoxicillin in Antibiotic-induced dysbiosis and gastrointestinal conditions, sponsored by Biocodex. Primary endpoint: Change in gut microbiota composition and diversity. Started Oct 2016; status: completed.
02
Drugs
saccharomyces boulardiiamoxicillin
03
Conditions
Antibiotic-induced dysbiosisgastrointestinal conditions
Beyond the preview
Go deeper on 2016-003654-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003654-33.